Eco R1 Capital, LLC Nurix Therapeutics, Inc. Transaction History

Eco R1 Capital, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$7.88 - $14.82 $2.01 Million - $3.77 Million	-254,473 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$12.94 - $29.65 $712,566 - $1.63 Million	-55,067 Reduced 17.79%	254,473 $3.57 Million
Q4 2021 Feb 14, 2022	SELL	$26.43 - $34.5 $21.6 Million - $28.2 Million	-817,100 Reduced 72.53%	309,540 $8.96 Million
Q3 2021 Nov 22, 2021	SELL	$22.71 - $36.69 $28.4 Million - $45.9 Million	-1,249,812 Reduced 52.59%	1,126,640 $33.8 Million
Q3 2021 Nov 15, 2021	BUY	$22.71 - $36.69 $9.28 Million - $15 Million	408,502 Added 20.76%	2,376,452 $59 Million
Q2 2021 Aug 16, 2021	SELL	$24.21 - $35.89 $1.24 Million - $1.83 Million	-51,069 Reduced 2.53%	1,967,950 $52.2 Million
Q1 2021 May 17, 2021	BUY	$26.98 - $50.17 $12.8 Million - $23.8 Million	475,000 Added 30.76%	2,019,019 $62.8 Million
Q4 2020 Feb 16, 2021	BUY	$22.85 - $48.44 $8.04 Million - $17 Million	351,863 Added 29.51%	1,544,019 $50.8 Million
Q3 2020 Nov 16, 2020	BUY	$16.05 - $34.91 $19.1 Million - $41.6 Million	1,192,156 New	1,192,156 $41.6 Million

181

68.1M

78K

53.8K

Ticker NRIX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,147,800
Market Cap $935M
Description
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...

Get notified when there are updates to the investment portfolio of Eco R1 Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Eco R1 Capital, LLC with notifications on news.